JOHNS HOPKINS TO ADD ELEKTA SYNERGY® S TO CANCER TREATMENT LINEUP

JOHNS HOPKINS TO ADD ELEKTA SYNERGY® S TO CANCER TREATMENT LINEUP

PRESS RELEASE	
Stockholm, Sweden, August 17, 2007

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, in
Maryland, USA, has placed an order to add an Elekta Synergy® S system to its
Leksell Gamma Knife® capability. A Stereotactic Center of Excellence, Johns
Hopkins aims to fight cancer with both intracranial and extracranial resources
for whole-body cancer treatment with the addition of Elekta Synergy S this fall.
Elekta Synergy S integrates high-resolution beam shaping, precise target
localization, organ motion control and 3D imaging into one package, taking
stereotactic radiosurgery and radiotherapy to a new level.

Theodore L. DeWeese, M.D., is Johns Hopkins professor of Radiation Oncology,
Oncology and Urology and chair of the Department of Radiation Oncology and
Molecular Radiation Sciences. “Elekta Synergy S is an ideal complement to
Leksell Gamma Knife radiosurgery,” says Dr. DeWeese. “With it, we are expanding
stereotactic radiosurgery to other parts of the anatomy besides the brain.” 

Elekta Synergy S: advanced stereotactic radiation

Elekta Synergy S is an image-guided robotic linear accelerator that combines
integrated software-driven imaging abilities with powerful high-resolution
radiation delivery. At Johns Hopkins' Kimmel Center, Elekta Synergy S will
enable specialists to perform both stereotactic radiosurgery and stereotactic
radiotherapy throughout the body, as well as, stereotactic radiosurgery on
cranial tumors unsuitable for Gamma Knife surgery.

Essentially, Elekta Synergy S provides Johns Hopkins with the two most important
ingredients for improved patient outcomes: 2D and ultra low dose 3D image-guided
accuracy and highly conformal beam shaping. This enables neurosurgeons at the
Kimmel Center to use extremely precise stereotactic radiosurgery and
stereotactic radiotherapy on small-field spinal tumors as well as paraspinal
indications with larger field-size requirements. 

Johns Hopkins' award-winning legacy

U.S. News & World Report recently named the Johns Hopkins Sidney Kimmel
Comprehensive Cancer Center third best in the nation and the top cancer hospital
in the Mid-Atlantic Region. The Johns Hopkins Hospital also ranked at the top of
its “America's Best Hospitals” Honor roll for the 17th consecutive year. 

Elekta Synergy S will be utilized for extracranial radiosurgery, particularly
spine and liver applications, says Dr. DeWeese. “The center expects to treat
approximately 20 patients per day with Elekta Synergy S in the first year,” he
says, “and about half of those will be stereotactic treatments. Hypofractionated
image-guided radiotherapy (IGRT) for prostate applications will follow at a
later date as well.” 

Johns Hopkins also will be using IMPAC for oncology-specific electronic medical
records (EMR). IMPAC, an Elekta company, takes oncology management to new levels
of efficiency with MOSAIQ™, an image-enabled oncology EMR. MOSAIQ supports all
aspects of treatment, from patient charting to billing to data and image
storage, as well as, patient assessments and access to online clinical images.

Elekta's history of innovation and its advancement of radiotherapy and
radiosurgery have made Elekta an industry leader. With the development of
Leksell Gamma Knife and the addition of Elekta Synergy S, and other advanced
linear accelerator systems, Elekta provides unprecedented precision, accuracy
and versatility in stereotactic radiosurgery and stereotactic radiotherapy.



******

For further information, please contact:

Peter Ejemyr, Group VP Corporate Communications, Elekta ABTel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com 

About Elekta

Elekta is an international medical-technology Group, providing meaningful
clinical solutions, comprehensive information systems and services for improved
cancer care and management of brain disorders. All of Elekta's solutions employ
non-invasive or minimally invasive techniques and are therefore clinically
effective, gentle on the patient and cost-effective. 

Clinical solutions include among others Leksell Gamma Knife® for non-invasive
treatment of brain disorders and Elekta Synergy® for image guided radiation
therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April
2005, the Elekta Group is the world's largest supplier of oncology software. 

Elekta's systems and solutions are used at over 4,000 hospitals around the world
to treat cancer and manage clinical operations as well as to diagnose and treat
brain disorders, including tumors, vascular malformations and functional
disorders. 

With approx. 2,000 employees, Elekta's corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.